Beam Therapeutics announced its third quarter 2026 financial results and clinical progress across its gene editing portfolio. Key highlights include updated Phase 1/2 data for BEAM-302 showing durable benefits for alpha-1 antitrypsin deficiency, plans to complete pivotal dosing by mid-2027, and initiation of BEAM-304 trials for phenylketonuria in early 2027. The company expects to submit a biologics license application for its sickle cell therapy, risto-cel, by the end of 2026. Beam ended Q3 with $1 billion in cash, supporting operations into mid-2029, and continues to advance multiple programs toward potential approvals and patient treatments.
Beam Therapeutics' third quarter 2026 financial results and clinical updates provide context for readers. For those following the health sector, here is Pluang's market snapshot as of Nov 03, 2026 19:02 WIB: out of 150 priced US health stocks, 74 rose and 69 fell. Notable movers include Koninklijke Philips NV (PHG) at USD 29.23 with a 1-day change of +5.94% and a typical hold time of 86 days on Pluang, Inovio Pharmaceuticals Inc (INO) at USD 1.78 down 5.56%, and Nuwellis Inc (NUWE) at USD 4.90 down 5.41%, with a notable Pluang order activity of 55% buy for NUWE.
Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...
Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...
Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...
Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...
Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...
